Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gambro lundia ab - glukoza, brezvodna; kalcijev klorid; kalijev klorid; magnezijev klorid; mlečna kislina; natrijev hidrogenkarbonat; natrijev klorid; kalijev klorid - raztopina za hemodializo/hemofiltracijo - glukoza, brezvodna 1,1 g / 1000 ml  kalcijev klorid0,26 g / 1000 ml  kalijev klorid0,15 g / 1000 ml  magnezijev klorid0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; kalcijev klorid 0,26 g / 1000 ml  kalijev klorid0,15 g / 1000 ml  magnezijev klorid0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; kalijev klorid 0,15 g / 1000 ml  magnezijev klorid0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; magnezijev klorid 0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; mlečna kislina 0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; natrijev hidrogenkarbonat 2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; natrijev klorid 6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; kalijev klorid 0,15 g / 1000 ml - zdravila za filtracijo krvi

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gambro lundia ab - glukoza, brezvodna; kalcijev klorid; kalijev klorid; magnezijev klorid; mlečna kislina; natrijev hidrogenkarbonat; natrijev klorid; kalijev klorid - raztopina za hemodializo/hemofiltracijo - glukoza, brezvodna 1,1 g / 1000 ml  kalcijev klorid0,26 g / 1000 ml  kalijev klorid0,15 g / 1000 ml  magnezijev klorid0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; kalcijev klorid 0,26 g / 1000 ml  kalijev klorid0,15 g / 1000 ml  magnezijev klorid0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; kalijev klorid 0,15 g / 1000 ml  magnezijev klorid0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; magnezijev klorid 0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; mlečna kislina 0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; natrijev hidrogenkarbonat 2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; natrijev klorid 6,13 g / 1000 ml  kalijev klorid0,15 g / 1000 ml; kalijev klorid 0,15 g / 1000 ml - zdravila za filtracijo krvi

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gambro lundia ab - glukoza, brezvodna; kalcijev klorid; kalijev klorid; magnezijev klorid; mlečna kislina; natrijev hidrogenkarbonat; natrijev klorid; kalijev klorid - raztopina za hemodializo/hemofiltracijo - glukoza, brezvodna 1,1 g / 1000 ml  kalcijev klorid0,26 g / 1000 ml  kalijev klorid0,3 g / 1000 ml  magnezijev klorid0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; kalcijev klorid 0,26 g / 1000 ml  kalijev klorid0,3 g / 1000 ml  magnezijev klorid0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; kalijev klorid 0,3 g / 1000 ml  magnezijev klorid0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; magnezijev klorid 0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; mlečna kislina 0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; natrijev hidrogenkarbonat 2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; natrijev klorid 6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; kalijev klorid 0,3 g / 1000 ml - zdravila za filtracijo krvi

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gambro lundia ab - glukoza, brezvodna; kalcijev klorid; kalijev klorid; magnezijev klorid; mlečna kislina; natrijev hidrogenkarbonat; natrijev klorid; kalijev klorid - raztopina za hemodializo/hemofiltracijo - glukoza, brezvodna 1,1 g / 1000 ml  kalcijev klorid0,26 g / 1000 ml  kalijev klorid0,3 g / 1000 ml  magnezijev klorid0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; kalcijev klorid 0,26 g / 1000 ml  kalijev klorid0,3 g / 1000 ml  magnezijev klorid0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; kalijev klorid 0,3 g / 1000 ml  magnezijev klorid0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; magnezijev klorid 0,1 g / 1000 ml  mlečna kislina0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; mlečna kislina 0,27 g / 1000 ml  natrijev hidrogenkarbonat2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; natrijev hidrogenkarbonat 2,94 g / 1000 ml  natrijev klorid6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; natrijev klorid 6,13 g / 1000 ml  kalijev klorid0,3 g / 1000 ml; kalijev klorid 0,3 g / 1000 ml - zdravila za filtracijo krvi

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ebewe pharma - docetaksel - koncentrat za raztopino za infundiranje - docetaksel 10 mg / 1 ml - docetaksel

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ebewe pharma - docetaksel - koncentrat za raztopino za infundiranje - docetaksel 10 mg / 1 ml - docetaksel

Evropska unija - slovenščina - EMA (European Medicines Agency)

warner chilcott uk ltd. - testosteron - spolne disfunkcije, psihološke - spolni hormoni in zdravila genitalni sistem, - intrinsa je indiciran za zdravljenje hipoaktivne spolne želje motnjo (hsdd) v dvostransko oophorectomised in hysterectomised (kirurško inducirane menopavze) ženske prejemajo sočasne estrogensko zdravljenje.

Evropska unija - slovenščina - EMA (European Medicines Agency)

warner chilcott  deutschland gmbh - testosteron - spolne disfunkcije, psihološke - spolni hormoni in zdravila genitalni sistem, - livensa je indicirano za zdravljenje hipoaktivne spolne želje motnjo (hsdd) v dvostransko oophorectomised in hysterectomised (kirurško inducirane menopavze) ženske prejemajo sočasne estrogensko zdravljenje.

Evropska unija - slovenščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - antineoplastična sredstva - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm limited - everolimus - tuberozna skleroza - antineoplastična sredstva - ledvična angiomyolipoma, povezanih z tuberous sklerozo kompleks (tsc)votubia je indiciran za zdravljenje odraslih bolnikov z ledvično angiomyolipoma, povezanih z tuberous sklerozo kompleks (tsc), ki so na tveganja za nastanek zapletov (ki temelji na dejavnikih, kot je velikost tumorja, prisotnost aneurysm, prisotnost ali več ali dvostranskih tumorji), ampak ki ne zahtevajo takojšnjo operacijo. dokazi, ki temeljijo na analizi sprememb v vsoto angiomyolipoma glasnosti. subependymal velikan celice astrocitoma (sega), ki je povezana z tuberous sklerozo kompleks (tsc)votubia je indiciran za zdravljenje bolnikov z subependymal velikan celice astrocitoma (sega), ki je povezana z tuberous sklerozo kompleks (tsc), ki zahtevajo terapevtski poseg, vendar niso podvržene operacijo. dokazi, ki temeljijo na analizi sprememb v sega glasnosti. nadaljnje klinične koristi, kot so izboljšanje bolezni, povezane simptome, ni bilo dokazano,.